Mifegyne (Mifepristone)

Mifepristone, the active ingredient in Mifegyne, is a progesterone receptor antagonist presented as a 200 mg tablet for oral use. It treats medical termination of intrauterine pregnancy up to 10 weeks gestation and is also used off‑label for management of Cushing's syndrome.

GNH USA supplies Mifegyne as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mifegyne (mifepristone) is employed in reproductive health and endocrine conditions where progesterone antagonism is required.

Medical termination of intrauterine pregnancy up to 10 weeks gestation: induces decidual breakdown and facilitates uterine expulsion. Medical abortion in combination with misoprostol: provides the initial pharmacologic step before prostaglandin‑mediated uterine contractions. Management of Cushing's syndrome (off‑label): blocks peripheral progesterone receptors and contributes to cortisol reduction when used with other agents.

Mifegyne may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea - Vomiting - Abdominal pain or cramping - Diarrhea - Fatigue - Headache

Serious or Rare Side Effects: - Heavy or prolonged vaginal bleeding - Infection (including sepsis) - Severe allergic reaction (anaphylaxis) - Liver injury (hepatotoxicity) - Uterine rupture - Deep vein thrombosis or pulmonary embolism

Mifegyne should be used only under qualified medical supervision with appropriate patient assessment.

Medical supervision: administration must be overseen by a qualified health professional. Gestational age verification: ensure pregnancy is ≤10 weeks before use. Contraindications: avoid in patients with adrenal insufficiency, chronic corticosteroid therapy, anticoagulant use, severe anemia, or an intrauterine device in place. Allergy: do not use if hypersensitivity to mifepristone or any tablet excipients. Drug interactions: review concomitant medications, especially anticoagulants and CYP inducers. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Mifegyne can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of severe bleeding. - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduced efficacy of mifepristone. - Systemic corticosteroids: may blunt intended hormonal effects.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase gastrointestinal discomfort. - Antihypertensives: monitor blood pressure for unexpected changes. - Antifungal azoles (e.g., ketoconazole): may raise plasma levels of mifepristone.